With the emergence of the COVID-19 pandemic, new variants of SARS-CoV-2 pose new challenges to existing antiviral drugs and vaccines. Expert teams of Creative Biolabs have mobilized to study human viral infections and to develop appropriate drugs and vaccines.
The lung is the primary target organ in the progress of COVID-19. In vivo, the alveolus is the core functional unit of the lung. Creative Biolabs attempted to build a human alveolar infection Covid-19-on-a-chip model using an organ chip that allows recapitulating the lung injury and immune response to viral infection in vitro at the organ level.
This model reflects the human-relevant responses of the alveolar-capillary barrier to viral infection by integrating multicellular components, tissue-tissue interface, fluid flow, and circulating immune cells, thus narrowing the gap between in vitro models and human organ pathophysiology.
Fig 1. The configuration of biomimetic human alveolus chip infected by SARS-CoV-2. (Zhang, 2020)
With our Covid-19-on-a-chip models used to study viral infection and its application in the investigation of underlying disease mechanisms and drug evaluation, related solutions for treating COVID-19 are presented. Our advanced disease-on-a-chip models will help you in new developmental directions for future studies in the fields of virology and drug evaluation for COVID-19.
Apart from the Covid-19-on-a-chip model, other models might capture your interest:
Broadening the scope of our disease-on-a-chip models, Creative Biolabs now introduces a range of 3D biology-based assay services meticulously designed to meet the specific requirements of our global clients. Connect with us to delve into the endless possibilities offered by our fine-tuned disease-on-a-chip models and to obtain any support you seek.
Reference